Bozkurt Kekilli et al. (2026) used Genomize-SEQ to analyze whole exome sequencing data from 12 patients with unexplained liver disease, identifying the genetic cause in one-third of cases. This shows that broad genomic testing can uncover rare inherited conditions missed by standard clinical tests.
Details
Paksoy et al. (2026) used multigene panel testing in 647 BRCA1/2-negative Turkish patients, with Genomize-SEQ supporting variant analysis. They identified clinically relevant non-BRCA variants in 16.2% of cases, led by CHEK2, ATM, and TP53.
Details
Yavas et al. (2026) used Genomize-SEQ to annotate and filter whole-exome sequencing data from a 7-year-old girl with unexplained cognitive impairment and microcephaly, identifying a novel homozygous ATP9A variant that structurally destabilizes the protein and underlies her neurodevelopmental disorder.
Details
Kose and Akalin (2026) used Genomize-SEQ to analyze NGS data from 52 pediatric IEI patients in a highly consanguineous Turkish population, establishing a molecular diagnosis in 63% of cases and directly influencing clinical management in 82% of diagnosed patients.
Details
Kayhan et al. (2026) identified pathogenic variants in 24% of 75 Turkish children presenting with ASD through Genomize-SEQ whole-exome analysis. This revealed underlying genetic diagnoses including Rett, Dravet, and Angelman syndrome in patients who had previously tested negative on standard screens.
Details
Genomize-SEQ CNV analysis in Durmaz et al. (2026) detected a TMC6 deletion that prompted optical genome mapping, revealing the first complex TMC6/TMC8 structural rearrangement in hereditary EV and four novel pathogenic variants across five Turkish families.
Details
Tarhan et al. (2026) used Genomize-SEQ to identify two KIF1C variants in 3 siblings with spastic ataxia, determining a splice-site mutation as the cause of hereditary spastic paraplegia, with cerebellar symptoms preceding pyramidal signs.
Details
Through Genomize-SEQ whole-exome variant analysis, Bolat et al. (2026) identified the 13th genetically confirmed Keipert syndrome case with a novel GPC4 missense variant, demonstrating that epilepsy without intellectual disability can accompany the condition.
Details
“Our collaboration with Genomize brings together Oxford Nanopore’s information- rich, rapid, and accessible molecular sensing platform with a powerful, clinically compliant analysis solution,” said Gordon Sanghera, CEO of Oxford Nanopore Technologies. “By optimising the processing of long-read data, we are enabling laboratories to translate complex genomic information into actionable insights with greater speed and confidence.”…
Details
“DKSH Indonesia’s unparalleled expertise and their deep-rooted presence makes them the ideal partner for us to provide our cutting-edge solutions to the clinicians and researchers. Together, we are not just expanding our commercial reach; we are deepening our commitment to advancing precision medicine and improving patient outcomes throughout Indonesia.” DKSH Indonesia and Genomize have entered…
Details